Clinical trials: ALS, open to volunteers
Amyotrophic Lateral Sclerosis
A Registered Cohort Study on Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a kind of motor neuron degeneration disorder without effective therapy. This registered cohort study will provide further insights into the clinical course of ALS, and investigate…
- Trial name
- NCT04008329
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Amyotrophic Lateral Sclerosis, Pseudobulbar Affect
Structural and Functional Networks in ALS: An Insight Into Pseudobulbar Affect
The investigators aim to elucidate characteristics of structural and functional brain connectivity in patients with amyotrophic lateral sclerosis (ALS) and pseudobulbar affect (PBA) using diffusion kurtosis imaging (DKI) and…
- Trial name
- NCT06396260
- Testing
- Diffusion Kurtosis Imaging (DKI), Resting State Magnetoencephalography
- Where
- Denmark
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Aalborg University Hospital
ALS, Respiratory Insufficiency
Combined Respiratory Training in Persons With ALS
The goal of this interventional trial is to learn about lung volume recruitment (LVR) and expiratory muscle strength training (EMST) in a total of up to 39 patients diagnosed with ALS. The following aims will be addressed: 1.
- Conditions
- ALS, Respiratory Insufficiency, Dysphagia
- Trial name
- NCT05913882
- Testing
- Respiratory Muscle Strength Training (LVR+EMST)
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Nova Southeastern University
Amyotrophic Lateral Sclerosis, Gastrointestinal Intolerance
Oral Intake of Enteral Nutrition Formula Preceding Placement and Feeding Via GTube and Its Impact on Formula Intolerance in pALS
The main objective of the proposed study is to evaluate if oral intake of EN formula preceding Gtube placement will impact tolerance upon placement and feeding via Gtube in pALS.
- Conditions
- Amyotrophic Lateral Sclerosis, Gastrointestinal Intolerance, Enteral Nutrition Therapy
- Trial name
- NCT06609213
- Testing
- Medical Food
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Andrea Charvet
Amyotrophic Lateral Sclerosis
Evaluating Verbal Communication in Structured Interactions: Theoretical and Clinical Implications
The goal of this clinical trial is to learn about the effect of communicative interaction on verbal communication in people with amyotrophic lateral sclerosis (ALS) and age-matched speakers.
- Trial name
- NCT06266403
- Testing
- Structured Communicative Interaction, Clear Speech, Unstructured communicative interaction
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Penn State University
Tetraplegia/Tetraparesis, Quadriplegia
UAE-PRIME: A Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices
The UAE-PRIME Study is a feasibility study designed to assess the initial clinical safety and functionality of the Neuralink N1 Implant and R1 Robot.
- Conditions
- Tetraplegia/Tetraparesis, Quadriplegia, Quadriplegia/Tetraplegia, Cervical Spinal Cord Injury
- Trial name
- UAE-PRIME (NCT06992596)
- Testing
- N1 Implant, R1 Robot
- Where
- United Arab Emirates
- Volunteers
- 10 people
- Sponsor
- Neuralink Corp
Alzheimer Disease, Parkinson Disease
hUC-MSC-sEV-001 Nasal Drops for Neurodegenerative Diseases
To evaluate the safety and preliminary efficacy of human umbilical cord mesenchymal stem cell-derived small extracellular vesicles hUC-MSC-sEV-001 nasal drops in multiple neurodegenerative diseases, including Alzheimer's disease…
- Conditions
- Alzheimer Disease, Parkinson Disease, Lewy Body Dementia, Multiple System Atrophy
- Trial name
- NCT06607900
- Testing
- hUC-MSC-sEV-001 nasal drops
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Xuanwu Hospital, Beijing
Amyotrophic Lateral Sclerosis
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
PIONEER-ALS is a Phase 1/2, multicenter, open-label, ascending dose, uncontrolled, first-in-human study that will evaluate the safety, tolerability and effects on clinical and biomarker endpoints of intracisternal administration…
- Trial name
- ALS (NCT07287397)
- Testing
- VTx-002, Preventative (Prophylactic) Medication - Corticosteroids: Methylprednisolone
- Where
- 9 sites in United States, Belgium and 2 more
- Volunteers
- 36 people
- Sponsor
- Vector Y Therapeutics
Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD)
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD), Alzheimer Disease (AD), Multiple Sclerosis (MS)
- Trial name
- NCT05395624
- Testing
- 18F-OP-801
- Where
- 3 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Ashvattha Therapeutics, Inc.
Amyotrophic Lateral Sclerosis
Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments
The aim of this project is to analyze the macrophage transcriptome and protein markers of Amyotrophic Lateral Sclerosis (ALS) patients compared to controls (non-affected individuals, patients with other motor impairments) and…
- Trial name
- Mac2ALS (NCT04816227)
- Where
- France
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Cardiac Arrest (CA)
Does Increasing the Compression Pause From 3 to 5 Seconds in Mechanical Compression Devices Increase Ventilation Success Rate and Return of Spontaneous Circulation?
To give chest compressions during cardiopulmonary resuscitation (CPR), mechanical chest compression devices can be used. During synchronous 30:2 CPR, the standard setting on these devices leave an automated 3-second chest…
- Trial name
- LUCASVP (NCT06824961)
- Testing
- 5-second ventilation pause duration during mechanical CPR, 3-second ventilation pause duration during mechanical CPR
- Where
- 2 sites in Netherlands
- Volunteers
- 692 people
- Sponsor
- Amsterdam UMC, location VUmc
Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS)
[18F]ACI-19626 PET in TDP-43 Proteinopathies
The goal of this clinical trial is to test whether we can reliably and safely measure the accumulation of pathological protein TDP-43 [involved in rare forms of dementia such as frontotemporal dementia (FTD) and in amyotrophic…
- Conditions
- Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS), TDP-43 Proteinopathies, Suspected Limbic Predominant Age-related TDP-43 Encephalopathy (LATE)
- Trial name
- NCT06891716
- Testing
- [18F]ACI-19626
- Where
- Netherlands
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- AC Immune SA
Amyotrophic Lateral Sclerosis (ALS), Bacillus Coagulans
A Study on the Addition of Alsum30 for the Treatment of Amyotrophic Lateral Sclerosis
This single-center, open-label pilot study will enroll approximately 15 adults with amyotrophic lateral sclerosis (ALS) to assess the safety and tolerability of adding Alsum30 to their care.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Bacillus Coagulans, Dietary Supplement, Sulforaphane
- Trial name
- NCT07922031
- Testing
- Sulforaphane and Bacillus coagulans GBI-30, 6086
- Volunteers
- 15 people
- Sponsor
- Liu Qing
Amyotrophic Lateral Sclerosis
Research of Traditional Chinese Medicine Oral Preparation of C. Cicadae in the Treatment of ALS Patients With Elevated Plasma Sphingolipids
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by the degeneration of motor neurons, leading to progressive muscle weakness and functional decline.
- Trial name
- NCT07467746
- Testing
- C. cicadae, Control
- Volunteers
- 84 people
- Sponsor
- The Third Xiangya Hospital of Central South University
Amyotrophic Lateral Sclerosis ALS
Intestinal Microbiome Transplant in ALS
This is a 24-week study of intestinal microbiome transplant in people with ALS. All participants will be evaluated clinically in person for 4 visits. Blood and mailed/ fresh stool samples will also be collected.
- Trial name
- NCT07017946
- Testing
- MTP-101C
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Duke University
Dementia, Alzheimer Disease
The Swedish BioFINDER 2 Study
The Swedish BioFINDER 2 study is a new study that will launch in 2017 and extends the previous cohorts of BioFINDER 1 study (www.biofinder.se). BioFINDER 1 is used e.g.
- Conditions
- Dementia, Alzheimer Disease, Parkinson Disease, Lewy Body Disease
- Trial name
- BioFINDER2 (NCT03174938)
- Testing
- Flutemetamol F18 Injection, [18F]-RO6958948, Elecsys (Roche) Abeta42, Ttau and Ptau
- Where
- 2 sites in Sweden
- Volunteers
- 2,950 people, healthy volunteers welcome
- Sponsor
- Skane University Hospital
ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis
Tongue-strengthening Exercises in People With ALS.
This study is testing a tongue exercise program for people living with ALS to see if it can help support speech and swallowing. All participants will receive the treatment, and researchers will measure changes over time by…
- Trial name
- NCT07295990
- Testing
- Isometric Lingual Strength Exercises
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Nova Southeastern University
ALS
Investigation of the Epidemiological Factors Associated With the Development of Amyotrophic Lateral Sclerosis (ALS)
Investigation of the epidemiological factors associated with amyotrophic lateral sclerosis (ALS) in Israel with a view to future international collaboration. Particularly addressing:- 1. Differences between ethnic subgroups 2.
- Trial name
- EpidALS (NCT03366506)
- Testing
- Observation
- Where
- Israel
- Volunteers
- 2,000 people
- Sponsor
- Hadassah Medical Organization
Amyotrophic Lateral Sclerosis
Nerve Growth Factor Encapsulated With 2-methacryloyloxyethyl Phosphorylcholine Nanocapsules in the Treatment of Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is one of the most lethal neurodegenerative diseases, with most patients dying from respiratory failure 3-5 years after the onset.
- Trial name
- NATURAL (NCT06391645)
- Testing
- Nerve Growth Factor
- Volunteers
- 60 people
- Sponsor
- Beijing Tiantan Hospital
Amyotrophic Lateral Sclerosis, ALS
A Study to Evaluate the Safety, Efficacy, and Pharmacodynamics of PLL001 in ALS Patients
FIH, Phase 1/2, multi-centre, randomised, double-blind, placebo controlled study with an optional open-label dosing extension to assess the safety, tolerability, efficacy, and Pharmacodynamics (PD) of single or multiple (up to 48…
- Trial name
- NCT06513546
- Volunteers
- 153 people
- Sponsor
- PLL TX AUSTRALIA PTY LTD